TD Asset Management Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 466,216 shares of the medical research company’s stock after purchasing an additional 137,656 shares during the period. TD Asset Management Inc. owned approximately 0.12% of Thermo Fisher Scientific worth $104,334,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the company. Essex Savings Bank bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $610,000. Creative Planning lifted its holdings in shares of Thermo Fisher Scientific by 6.9% in the fourth quarter. Creative Planning now owns 28,446 shares of the medical research company’s stock valued at $6,366,000 after purchasing an additional 1,831 shares in the last quarter. Dupont Capital Management Corp lifted its holdings in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. Dupont Capital Management Corp now owns 29,521 shares of the medical research company’s stock valued at $6,607,000 after purchasing an additional 684 shares in the last quarter. Cavalier Investments LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $1,061,000. Finally, SeaTown Holdings Pte. Ltd. raised its holdings in Thermo Fisher Scientific by 74.0% during the fourth quarter. SeaTown Holdings Pte. Ltd. now owns 112,000 shares of the medical research company’s stock worth $25,064,000 after acquiring an additional 47,649 shares in the last quarter. Institutional investors own 91.80% of the company’s stock.
In other Thermo Fisher Scientific news, insider Gregory J. Herrema sold 17,235 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $247.00, for a total value of $4,257,045.00. Following the sale, the insider now owns 26,446 shares in the company, valued at $6,532,162. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Tyler Jacks sold 4,772 shares of the company’s stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $239.75, for a total value of $1,144,087.00. The disclosure for this sale can be found here. Insiders sold 32,607 shares of company stock worth $7,972,085 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.
NYSE:TMO traded up $1.67 on Monday, hitting $245.18. The company’s stock had a trading volume of 308,695 shares, compared to its average volume of 1,696,646. The company has a quick ratio of 1.23, a current ratio of 1.71 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $98.03 billion, a price-to-earnings ratio of 22.05, a P/E/G ratio of 1.60 and a beta of 1.14. Thermo Fisher Scientific Inc. has a one year low of $194.51 and a one year high of $253.91.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.19 by $0.06. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.79 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 12.14 EPS for the current year.
Several analysts recently issued reports on TMO shares. Cleveland Research lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Thursday, October 18th. Robert W. Baird upped their target price on Thermo Fisher Scientific from $256.00 to $264.00 and gave the stock an “outperform” rating in a report on Thursday, October 25th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $254.00 to $260.00 and gave the stock an “overweight” rating in a report on Thursday, October 25th. Finally, Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $247.00 target price on the stock in a report on Friday, October 26th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Thermo Fisher Scientific has an average rating of “Buy” and a consensus target price of $275.10.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: Beta